124 related articles for article (PubMed ID: 19179633)
1. Tainted heparin crisis tested FDA's investigative skills.
Lavine G
Am J Health Syst Pharm; 2009 Feb; 66(3):210-1. PubMed ID: 19179633
[No Abstract] [Full Text] [Related]
2. From crisis to opportunity: a perspective on the heparin crisis.
Sasisekharan R; Shriver Z
Thromb Haemost; 2009 Nov; 102(5):854-8. PubMed ID: 19888519
[No Abstract] [Full Text] [Related]
3. The tainted heparin story: an update.
Guerrini M; Shriver Z; Bisio A; Naggi A; Casu B; Sasisekharan R; Torri G
Thromb Haemost; 2009 Nov; 102(5):907-11. PubMed ID: 19888527
[TBL] [Abstract][Full Text] [Related]
4. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008.
McMahon AW; Pratt RG; Hammad TA; Kozlowski S; Zhou E; Lu S; Kulick CG; Mallick T; Dal Pan G
Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):921-33. PubMed ID: 20661880
[TBL] [Abstract][Full Text] [Related]
5. Lessons learned from the contamination of heparin.
Liu H; Zhang Z; Linhardt RJ
Nat Prod Rep; 2009 Mar; 26(3):313-21. PubMed ID: 19240943
[TBL] [Abstract][Full Text] [Related]
6. Changes in the USP heparin monograph and implications for clinicians.
Smythe MA; Nutescu EA; Wittkowsky AK
Pharmacotherapy; 2010 May; 30(5):428-31. PubMed ID: 20411994
[No Abstract] [Full Text] [Related]
7. [Artificial polysaccharide in contaminated heparin. Acute hypersensitivity reactions explained--but how could it happen?].
Lindahl U
Lakartidningen; 2008 Sep 24-30; 105(39):2660-1. PubMed ID: 18846871
[No Abstract] [Full Text] [Related]
8. Contaminant in the recalled unfractionated heparin preparations: where is the problem?
Hoppensteadt DA; Wahi R; Adiguzel C; Iqbal O; Ramacciotti E; Bick RL; Messmore HL; Bansal V; Fareed J
Clin Appl Thromb Hemost; 2008 Jul; 14(3):261-6. PubMed ID: 18565985
[No Abstract] [Full Text] [Related]
9. [Anaphylactoid reactions associated with contaminated heparin from China].
Montpas N; Désormeaux A; Keire D; Adam A
Ann Pharm Fr; 2011 Sep; 69(5):258-64. PubMed ID: 21924126
[TBL] [Abstract][Full Text] [Related]
10. Contaminants in heparins continue to be unfolded.
Fareed J; Ahluwalia M; Wahi R; Ramaccioti E; Hoppensteadt D; Bick RL
Int Angiol; 2008 Dec; 27(6):457-61. PubMed ID: 19078906
[No Abstract] [Full Text] [Related]
11. Contaminated heparin preparations, severe adverse events and the contact system.
Ramacciotti E; Wahi R; Messmore HL
Clin Appl Thromb Hemost; 2008 Oct; 14(4):489-91. PubMed ID: 18815138
[No Abstract] [Full Text] [Related]
12. Lessons from contaminated heparin.
Dodd S; Besag FM
Curr Drug Saf; 2009 Jan; 4(1):1. PubMed ID: 19149518
[No Abstract] [Full Text] [Related]
13. Outbreak of adverse reactions associated with contaminated heparin.
Blossom DB; Kallen AJ; Patel PR; Elward A; Robinson L; Gao G; Langer R; Perkins KM; Jaeger JL; Kurkjian KM; Jones M; Schillie SF; Shehab N; Ketterer D; Venkataraman G; Kishimoto TK; Shriver Z; McMahon AW; Austen KF; Kozlowski S; Srinivasan A; Turabelidze G; Gould CV; Arduino MJ; Sasisekharan R
N Engl J Med; 2008 Dec; 359(25):2674-84. PubMed ID: 19052120
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and detection of N-sulfonated oversulfated chondroitin sulfate in marketplace heparin.
Mans DJ; Ye H; Dunn JD; Kolinski RE; Long DS; Phatak NL; Ghasriani H; Buhse LF; Kauffman JF; Keire DA
Anal Biochem; 2015 Dec; 490():52-4. PubMed ID: 26278168
[TBL] [Abstract][Full Text] [Related]
15. Oversulfated chondroitin sulfate is not the sole contaminant in heparin.
Pan J; Qian Y; Zhou X; Pazandak A; Frazier SB; Weiser P; Lu H; Zhang L
Nat Biotechnol; 2010 Mar; 28(3):203-7; author reply 207-11. PubMed ID: 20212477
[No Abstract] [Full Text] [Related]
16. [Contaminated heparins].
Monneret C
Ann Pharm Fr; 2008 Aug; 66(4):212-5. PubMed ID: 18847567
[TBL] [Abstract][Full Text] [Related]
17. Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market.
Beyer T; Matz M; Brinz D; Rädler O; Wolf B; Norwig J; Baumann K; Alban S; Holzgrabe U
Eur J Pharm Sci; 2010 Jul; 40(4):297-304. PubMed ID: 20399266
[TBL] [Abstract][Full Text] [Related]
18. The use of circular dichroism as a simple heparin-screening strategy.
Stanley FE; Stalcup AM
Anal Bioanal Chem; 2011 Jan; 399(2):701-6. PubMed ID: 20953771
[TBL] [Abstract][Full Text] [Related]
19. Characterization of currently marketed heparin products: key tests for quality assurance.
Keire DA; Ye H; Trehy ML; Ye W; Kolinski RE; Westenberger BJ; Buhse LF; Nasr M; Al-Hakim A
Anal Bioanal Chem; 2011 Jan; 399(2):581-91. PubMed ID: 20680615
[TBL] [Abstract][Full Text] [Related]
20. Contaminated heparin.
Greinacher A; Warkentin TE
N Engl J Med; 2008 Sep; 359(12):1291-2; author reply 1293. PubMed ID: 18799565
[No Abstract] [Full Text] [Related]
[Next] [New Search]
